1004316-18-0

Basic information

• Product Name: thiazol-5-ylmethyl ((2R,5R)-5-amino-1,6-diphenylhexan-2-yl)carbamate
• Synonyms: thiazol-5-ylmethyl ((2R,5R)-5-amino-1,6-diphenylhexan-2-yl)carbamate;N-[(1R,4R)-4-Amino-5-phenyl-1-(phenylmethyl)pentyl]carbamic acid 5-thiazolylmethyl ester
• CAS NO: 1004316-18-0
• Molecular Formula: C₂₃H₂₇N₃O₂S
• Molecular Weight: 409.54438
• Mol File: 1004316-18-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: thiazol-5-ylmethyl ((2R,5R)-5-amino-1,6-diphenylhexan-2-yl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: thiazol-5-ylmethyl ((2R,5R)-5-amino-1,6-diphenylhexan-2-yl)carbamate(1004316-18-0)
• EPA Substance Registry System: thiazol-5-ylmethyl ((2R,5R)-5-amino-1,6-diphenylhexan-2-yl)carbamate(1004316-18-0)

Safety Data

• Hazardous Substances Data: 1004316-18-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Thiazol-5-ylmethyl ((2R,5R)-5-amino-1,6-diphenylhexan-2-yl)carbamate is used as an intermediate in the synthesis of Cobicistat (O849600), an HIV protease inhibitor. It plays a crucial role in the development of antiretroviral drugs, contributing to the fight against HIV/AIDS.
Additionally, it is used in the synthesis of 9-(Desmorpholinylethyl) 7,9-(1-Hydroxyethylene) Cobicistat (D296915), an impurity of Cobicistat. thiazol-5-ylmethyl ((2R,5R)-5-amino-1,6-diphenylhexan-2-yl)carbamate has been coadministered with low-dose ritonavir (R535000) as a pharmacoenhancer, significantly increasing their plasma concentrations. This application highlights the importance of thiazol-5-ylmethyl ((2R,5R)-5-amino-1,6-diphenylhexan-2-yl)carbamate in enhancing the effectiveness of HIV treatments and improving patient outcomes.

Upstream product

• 144186-34-5 (2R,5R)-1,6-diphenylhexane-2,5-diamine 
• 144163-97-3 ((5-thiazolyl)methyl)-(4-nitrophenyl)carbonate 
• 1448312-70-6 1,6-diphenyl-5(S)-tert-butoxycarbonylamino-2(S)-(5-thiazolemethoxy)carbonylamino-hexane 
• 2577-90-4 methyl (2S)-2-amino-3-phenylpropanoate 
• 51987-73-6 (S)-2-tert-butoxycarbonylamino-3-phenyl-propionic acid methyl ester 

Downstream Products

• 1004316-19-1 C₃₉H₅₀N₆O₄S₂ 
• 1004318-04-0 C₃₂H₄₂N₄O₆S 
• 1004318-14-2 C₂₄H₂₉N₃O₂S 

Relevant articles and documents

A method for preparing may compared to the department he intermediate and intermediate thereof and use thereof

The invention relates to the field of medicinal chemical synthesis, in particular to a cobicistat intermediate preparing method, an intermediate and application thereof. The cobicistat intermediate (a compound (4)) preparing method includes the steps that a compound (5) is prepared into an organic metal compound (5'), and the compound (5') reacts with a compound (6) to prepare the compound (4) (see the reaction process in the description). The new reaction raw material compound (5) or (6) is provided to obtain the new compound (4) preparing method, the overall yield of the reaction can be increased, usage of toxic reagents is avoided, side reactions are reduced, and the cobicistat intermediate preparing method is suitable for industrial production. Further, the compound (4) is used as the intermediate for preparing a compound (1), by-products in the prior art are avoided, usage of toxic reagents is avoided, cost is saved, and the intermediate is beneficial for environment maintenance and suitable for industrial production.

MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS

The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.